Please assess the completion status of the following clinical trial:

Trial Title: Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of CVD (defined as documented coronary artery disease, stroke, or peripheral artery disease).~* Fasting serum triglycerides (TG) greater than or equal to (≥) 200 milligrams per deciliter (mg/dL) (≥ 2.3 millimoles per liter (mmol/L)) and less than or equal to (≤) 500 mg/dL (≥ 5.7 mmol/L) at Screening.~* Fasting TG ≥ 200 mg/dL and ≤ 500 mg/dL at Qualification visit.~* Must be on standard-of-care preventative therapy for known CVD risk factors.~Key Exclusion Criteria:~* Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or stroke/transient ischemic attack (TIA).~* Within 3 months of Screening: coronary, carotid, or peripheral arterial revascularization, major non-cardiac surgery, or lipoprotein apheresis.~* Heart failure New York Heart Association (NYHA) class IV.~* Type 1 diabetes mellitus.~* Type 2 diabetes mellitus with any of the following:~  * Newly diagnosed within 12 weeks of Screening.~ * Glycated hemoglobin (HbA1c) ≥ 9.0% at Screening.~ * Recent change in anti-diabetic pharmacotherapy (change in dosage or addition of new medication within 12 weeks of Screening \[with the exception of ± 10 units of insulin\].~* Body Mass Index (BMI) greater than (\>) 40 kilograms per square meter (kg/m\^2).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pooled Placebo (Type: PLACEBO_COMPARATOR): Participants in each cohort (A, B, C and D) were randomized to receive placebo at a dose-matched volume of study drug (ISIS 678354).
- Cohort A: ISIS 678354: 10 mg Q4W (Type: EXPERIMENTAL): Cohort A participants received 10 milligrams (mg) ISIS 678354, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
- Cohort C: ISIS 678354: 15 mg Q2W (Type: EXPERIMENTAL): Cohort C participants received 15 mg ISIS 678354, SC injection, once every 2 weeks (Q2W) for up to 51 weeks and a maximum of 26 doses.
- Cohort D: ISIS 678354: 10 mg QW (Type: EXPERIMENTAL): Cohort D participants received 10 mg ISIS 678354, SC injection, once weekly (QW) for up to 52 weeks and a maximum of 52 doses.
- Cohort B: ISIS 678354: 50 mg Q4W (Type: PLACEBO_COMPARATOR): Cohort B participants received 50 mg ISIS 678354, SC injection, once Q4W for up to 49 weeks and a maximum of 13 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).